Once-weekly subcutaneous tirzepatide may not raise risk for depression compared with placebo, according to a post hoc analysis of the SURMOUNT trials. As Healio previously reported, in January the FDA ...
null ...
null ...
In this article we explore the latest developments in UK and EU Sustainability and ESG regulation in financial services, including ...
It started with a sign that seemed simple enough. Posted at the longtime ShopRite along Route 72, it announced the store’s relocation to 733 Route 72 West, Manahawkin. For many drivers, especially ...
The recall is classified as Class III, the FDA’s lowest risk level, meaning it’s “not likely to cause adverse health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results